Researchers Launch New Alzheimer's Prevention Trial
The clinical study tests medication combinations to prevent disease onset in carriers of a specific genetic mutation.
Updated on Oct. 15, 2026 in Alzheimer’s
Live Poll
Should medical research prioritize aggressive prevention trials for populations with a high genetic disease risk?
Scientists have officially enrolled the first participant in a new clinical trial aimed at preventing Alzheimer's disease in individuals with the PSEN1 genetic mutation. This study examines whether antibody therapies and other drugs can effectively limit amyloid protein production and clear plaques before symptoms appear.
Why it matters
Researchers aim to determine if early intervention with specific drug combinations can successfully delay or prevent Alzheimer's in populations at the highest genetic risk. This trial could fundamentally change how clinicians approach neurodegenerative disease in patients who are genetically predisposed to an early onset of cognitive decline.
The study targets a cohort of 1,200 PSEN1 mutation carriers who typically develop Alzheimer's by age 44. Participants are divided into four treatment groups, supported by $74.5 million from the National Institute on Aging and $3 million from the NOMIS Foundation.
The players
Banner Alzheimer's Institute
This organization is based in Phoenix, Arizona, and focuses on advancing the research and treatment of Alzheimer's disease through large-scale clinical trials.
University of Antioquia
Located in Medellín, Colombia, this institution provides critical local infrastructure for the study of the large kindred group carrying the PSEN1 mutation.
National Institute on Aging
This federal agency is part of the U.S. National Institutes of Health and supports research into the aging process and age-related health conditions.
NOMIS Foundation
Headquartered in Zurich, Switzerland, this foundation funds basic and clinical scientific research that seeks to foster breakthroughs in understanding complex human problems.
The details
The trial utilizes donanemab to clear existing amyloid plaques and Roche's nivagacetor to limit protein production, with participants randomly assigned to one of four arms. This research is led by the Banner Alzheimer's Institute in collaboration with the University of Antioquia to leverage data from the Colombian kindred.
Timeline
The Alzheimer's Prevention Initiative was formed in 2009.
The first API ADAD Colombia trial was announced in 2012.
The first participant was assigned to the new treatment trial on October 15, 2026.
The Big Picture
This clinical trial follows a pattern set by the Alzheimer's Prevention Initiative by testing new drug regimens in high-risk genetic populations. The research builds upon previous long-term assessments to evaluate whether prophylactic treatments can alter the disease's natural course.
This study provides a roadmap for future preventive medicine by testing whether early-stage interventions can manage amyloid levels before symptoms manifest. If successful, the findings could eventually transform standard preventative care protocols for individuals with familial genetic risks.
The takeaway
This trial represents a shift toward aggressive, early-intervention strategies for neurodegenerative conditions. It highlights the critical importance of identifying and studying specific genetic kindreds to unlock effective preventative therapies.
Further reading
Learn more about ongoing research into Alzheimer’s and its potential treatments.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical research prioritize aggressive prevention trials for populations with a high genetic disease risk?
